JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

NCT06716658 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, T-Cell
NK-LGL Leukemia
T-LGL Leukemia
Cutaneous T Cell Lymphoma
Cutaneous T Cell Lymphoma (CTCL)
Large Granular Lymphocyte Leukemia
Large Granular Lymphocytic Leukemia
Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract
Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma
Mycosis Fungoides

Interventions

DRUG: JAK1 Inhibitor

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]